Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2010, vol. 19, nr 3, May-June, p. 399–404

Publication type: review article

Language: English

Visfatin/PBEF/Nampt and Other Adipocytokines in Inflammatory Bowel Disease

Wisfatyna/PBEF/Nampt i inne adipocytokiny w nieswoistych zapaleniach jelit

Katarzyna Neubauer1,, Małgorzata Krzystek-Korpacka2,

1 Department of Gastroenterology and Hepatology, Wroclaw Medical University, Poland

2 Department of Medical Biochemistry, Wroclaw Medical University, Poland

Abstract

Etiopathogenesis of inflammatory bowel disease (IBD), chronic devastating conditions of the gastrointestinal tract, remains unclear. As a consequence, the effective and safe treatment strategy and ideal biochemical disease marker are still missing. IBD are associated with many nutritional problems (cachexia, microand macroelements deficiencies) and additionally there is an abnormal visceral fat structure in Crohn’s disease. Thus, potential involvement of adipocytokines, fat-derivate mediators, in the development of inflammatory bowel disease is extensively studied. List of adipocytokines is growing and currently involves: visfatin/PBEF/Nampt, resistin, adiponectin, apelin, leptin, hepcidin, vaspin, chemerin, omentin, and RBP-4. Adipocytokines possess pleiotropic properties. Visfatin/PBEF/ Nampt acts as a cytokine, growth factor and enzyme. It is suggested that visfatin/PBEF/Nampt participates in the development of inflammation-related bone disease. Elucidation of role of adipocytokines in inflammatory bowel disease requires further studies.

Streszczenie

Etiopatogeneza nieswoistych zapaleń jelit (n.z.j.), przewlekłych, wyniszczających chorób przewodu pokarmowego pozostaje niejasna. W związku z tym wciąż nie istnieje ani w pełni skuteczna i bezpieczna strategia terapeutyczna, ani doskonały biochemiczny wskaźnik choroby. Istotnym problemem związanym z n.z.j. są zaburzenia stanu odżywienia (niedożywienie, niedobory mikroi makroelementów), a w przypadku choroby Leśniowskiego-Crohna zaburzona struktura tkanki tłuszczowej w jamie brzusznej. Dlatego bada się możliwy udział w rozwoju nieswoistych zapaleń jelit substancji pochodzących z tkanki tłuszczowej, tzw. adipocytokin. Lista adipocytokin stale rośnie i obecnie obejmuje: wisfatynę/PBEF/Nampt, rezystynę, adiponektynę, apelinę, leptynę, hepcydynę, waspinę, omentynę, RBP-4. Adipocytokiny mają wielokierunkowe działanie. Wisfatyna/PBEF/Nampt ma właściwości cytokiny, czynnika wzrostu i enzymu. Sugeruje się, że wisfatyna/PBEF/Nampt bierze udział w rozwoju związanej z zapaleniem choroby kości. Wyjaśnienie roli adipocytokin w nieswoistych zapaleniach jelit wymaga dalszych badań.

Key words

adipocytokines, visfatin/PBEF/Nampt, adiponectine, inflammatory bowel disease

Słowa kluczowe

adipocytokiny, wisfatyna, adiponektyna, nieswoiste zapalenia jelit

References (34)

  1. Neubauer K, Sadakierska-Chudy A, Poniewierka E: Znaczenie kliniczne CARD15 i nowe geny podatności na chorobę Leśniowskiego-Crohna. Gastroenterol Pol 2008, 15, 111–114.
  2. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008, 14, 4280–4288.
  3. Hoentjen F, van Bodegraven AA: Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009, 15, 2067–2073.
  4. Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006, 55, 426–431.
  5. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B cell colony-enhancing factor. Mol Cell Biol 1994, 14, 1431–1437.
  6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakamiv H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307, 426.
  7. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S-I: Nampt/PBEF/visfatin regulates insulin secretion in β cells as asystemic NAD biosynthetic enzyme. Cell Metab 2007, 6, 363–375.
  8. Krzysik-Walker SM, Ocón-Grove OM, Maddineni SR, Hendricks III GL, Ramachandran R: Is Visfatin an Adipokine or Myokine? Evidence for Greater Visfatin Expression in Skeletal Muscle than Visceral Fat in Chickens. Endocrinology 2008, 149, 1543–1550.
  9. Adeghate E: Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008, 15, 1851–1862.
  10. Wang SN, Yeh YT, Wang ST, Chuang SC, Wang CL, Yu ML, Lee KT: Visfatin-a proinflammatory adipokine – in gallstone disease. Am J Surg 2010, 199, 459–465.
  11. De Boer JF, Bahr MJ, Böker KH, Manns MP, Tietge UJ: Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009, 296, G196–201.
  12. Morgan SA, Bringolf JB, Seidel ER: Visfatin expression is elevated in normal human pregnancy. Peptides 2008, 29, 1382–1389.
  13. Chang YC, Chang TJ, Lee WJ, Chuang LM: The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010, 59, 93–99.
  14. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J, Kiess W: Molecular Characteristics of Serum Visfatin and Differential Detection by Immunoassays. J Clin Endocrinol Metab 2007, 92, 4783–4791.
  15. Chen MP, Chung FM, Chang DM, Tsai J, Huang HF, Shin SJ, Lee YL: Elevated Plasma Level of Visfatin/Pre-B Cell Colony-Enhancing Factor in Patients with Type 2 Diabetes Mellitus. J Clin Endocrin Metab 2006, 91, 295– 299.
  16. Samara A, Pfister M, Berangere M, Visvikis-Siest S: Visfatin, low-grade inflammation and body mass index (BMI). Clin Endocrinol 2008, 69, 568–574.
  17. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M: Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54, 2911–2916.
  18. Li L, Yang G, Shi S, Yang M, Liu H, Boden G: The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine 2009, 45, 12–19.
  19. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, Kyburz D: Pre-B cell colony enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 2007, 56, 2829–2839.
  20. O’Sullivan M, O’Morain: Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2006, 20, 561–573.
  21. Sheehan AL, Warren BF, Gear MW, Shepherd NA: Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg 1992, 79, 955–958.
  22. Batra A, Zeitz M, Siegmund B: Adipokine Signaling in Inflammatory Bowel Disease. Inflamm Bowel Dis 2009, 15, 1897–1905.
  23. Gambero A, Maro´stica M, Abdalla Saad MJ, Pedrazzoli Jr J: Mesenteric Adipose Tissue Alterations Resulting from Experimental Reactivated Colitis. Inflamm Bowel Dis 2007, 13, 1357–1364.
  24. Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, Ito T, Nezu R, Tsutsui J, Miyagawa J-I, Tamura S, Matsuzawa Y, Shimomura I, Shinomura Y: Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn’s disease. Gut 2005, 54, 789–796.
  25. Paul G, Schäffler A, Neumeier M, Fürst A, Bataillle F, Buechler C, Müller-Ladner U, Schölmerich J, Rogler G, Herfarth H: Profiling Adipocytokine Secretion from Creeping Fat in Crohn’s Disease. Inflamm Bowel Dis 2006, 12, 471–477.
  26. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA: Circulating levels of leptin, adiponectin, resistin and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12, 100–105.
  27. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Oschenskuhn T, Parhofer KG, Goke B, Broedl UC: Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007, 19, 1070–1074.
  28. Weigert J, Obermeier F, Neumeier M, Wanninger J, Filarsky M, Bauer S, Aslanidis C, Rogler G, Ott C, Schaffler A, Scholmerich J, Beuchler C: Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis 2020, 16, 630–637.
  29. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis EA: The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2007, 19, 789–794.
  30. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomudalting properties. J Immunol 2007, 178, 1748–1758.
  31. Valentini L, Wirth EK, Schweizer U, Hengstermann S, Schaper L, Koernicke T, Dietz E, Norman K, Buning C, Winklhofer-Roob BM, Lochs H, Ockenga J: Circulating adipocytokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009, 25, 172–181.
  32. Kuwabara A, Tanaka K, Tsugawa N, Nakase H, Tsuji H, Shide K, Kamao M, Chiba T, Inagaki N, Okano T, Kido S: High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int 2009, 20, 935–942.
  33. Moschen AR, Geiger S, Gerner R, Tilg H: Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 2009 Jul 5.
  34. Luk T, Malam Z, Marshall JC: Pre-B cell colon-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008, 83, 804–816.